Bruce Liu, Shiyi He, Ivy Jiang, Duo Xu, Selene Peng

Bruce Liu leads Simon-Kucher’s Life Sciences division in Greater China. He has over 20 years of experience in the life sciences industry and is recognized as a thought leader on key industry topics, with recent publications on medtech access trends, reimbursement listing outlooks, business model innovations, and globalization strategy.

Shiyi He is a consultant with extensive experience in health economics and payer strategies in China.

Ivy Jiang is a consultant with years of experience in China pharmaceutical pricing and access strategies.

Duo Xu is a consultant specialized in China pharma and healthcare industry with recent experience on NRDL renewals.

Selene Peng is a consultant with experience across diverse therapeutic areas, and recent experience on NRDL trends and outlook.


China 2021 National Reimbursement Drug List Outlook

The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.